Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

MYSTERIOUS: Neurocrine biosciences earnings perspective return on capital employed - You Need To See This

According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60 million, a 0.45% change since Q4. In Q4, Neurocrine Biosciences brought in $312.00 million in sales but lost $7.30 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.